

REGISTERED NUMBER: 12215708 (England and Wales)

FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
FOR
VANGUARD MEDICAL DEVICES LIMITED

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

	Page
Company Information	1
Statement of Financial Position	2
Notes to the Financial Statements	3

VANGUARD MEDICAL DEVICES LIMITED

**COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2025**

DIRECTOR: Ulrike Marczak

SECRETARY: JTC (UK) Limited

REGISTERED OFFICE: The Scalpel
18th Floor,
52 Lime Street
London
EC3M 7AF

REGISTERED NUMBER: 12215708 (England and Wales)

AUDITORS: Ad Valorem Audit Services Limited
Chartered Certified Accountants & Statutory
Auditors
2 Manor Farm Court
Old Wolverton Road
Old Wolverton
Milton Keynes
Buckinghamshire
MK12 5NN

VANGUARD MEDICAL DEVICES LIMITED (REGISTERED NUMBER: 12215708)

**STATEMENT OF FINANCIAL POSITION
31 DECEMBER 2025**

		2025		2024 as restated	
	Notes	£	£	£	£
FIXED ASSETS					
Tangible assets	4		2,309		1,228
CURRENT ASSETS					
Stocks		16,969		-	
Debtors	5	171,592		26,463	
Cash at bank		69,131		8,128	
		257,692		34,591	
CREDITORS					
Amounts falling due within one year	6	515,606		148,798	
NET CURRENT LIABILITIES			(257,914)		(114,207)
TOTAL ASSETS LESS CURRENT LIABILITIES			(255,605)		(112,979)
CREDITORS					
Amounts falling due after more than one year	7		1,520,827		1,394,547
NET LIABILITIES			(1,776,432)		(1,507,526)
CAPITAL AND RESERVES					
Called up share capital	8		1		1
Retained earnings			(1,776,433)		(1,507,527)
SHAREHOLDERS' FUNDS			(1,776,432)		(1,507,526)

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 20 May 2026 and were signed by:

Ulrike Marczak - Director

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025**

1. STATUTORY INFORMATION

Vanguard Medical Devices Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

TURNOVER

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

TANGIBLE FIXED ASSETS

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - 33% on cost

STOCKS

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

TAXATION

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

DEFERRED TAX

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

FOREIGN CURRENCIES

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the statement of financial position date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2025

2. ACCOUNTING POLICIES - continued

PENSION COSTS AND OTHER POST-RETIREMENT BENEFITS

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

GOING CONCERN

The company made a loss for the year ended 31 December 2025 of £268,906 (2024: £49,337) and had a balance sheet deficiency of £1,776,432 (2024: £1,507,526) at that date and, as a consequence, is dependent upon the support of its parent company to continue as a going concern. These conditions indicate that a material uncertainty exists that may cast doubt on the company's ability to continue as a going concern.

PARENT COMPANY

The immediate parent undertaking of Vanguard Medical Devices LTD is Vanguard AG, a Company incorporated in Germany with registered office at Landsberger Str. 222, 12623 Berlin, Deutschland.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2024 - 3) .

4. TANGIBLE FIXED ASSETS

	Computer equipment £
COST	
At 1 January 2025	2,152
Additions	1,728
At 31 December 2025	<u>3,880</u>
DEPRECIATION	
At 1 January 2025	924
Charge for year	647
At 31 December 2025	<u>1,571</u>
NET BOOK VALUE	
At 31 December 2025	<u>2,309</u>
At 31 December 2024	<u>1,228</u>

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024 as restated
	£	£
Trade debtors	167,441	-
Amounts owed by group undertakings	-	23,985
Other debtors	4,151	2,478
	<u>171,592</u>	<u>26,463</u>

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2025

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024 as restated
	£	£
Trade creditors	32,103	1,886
Amounts owed to group undertakings	354,983	-
Taxation and social security	27,660	78,225
Other creditors	100,860	68,687
	<u>515,606</u>	<u>148,798</u>

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2025	2024 as restated
	£	£
Amounts owed to group undertakings	<u>1,520,827</u>	<u>1,394,547</u>

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	2025	2024 as restated
			£	£
1	Ordinary share	£1	<u>1</u>	<u>1</u>

9. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Zubair Arshad (FCCA, ACA) (Senior Statutory Auditor)
for and on behalf of Ad Valorem Audit Services Limited

10. RELATED PARTY DISCLOSURES

During the year, the company operated loans with its parent company. The total amount outstanding as at the year-end date was £1,875,810 (2024: £1,370,563), of which £354,983 is included within current liabilities and the remaining £1,520,827 is classified as liabilities due after more than one year. Interest is charged on the loans at a rate of 2.5% per annum.

11. ULTIMATE CONTROLLING PARTY

Mr Thomas Peter Maier is the controlling party.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.